Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497817 | 0.95 | CCNC (0.46) | CCNCCDK8ALDH1A1GFERMAPKAPK2 | |
| SCHEMBL5499689 | 0.89 | CA12 (0.38) | CCNCCDK8CSNK1DALDH1A1GFER | |
| SCHEMBL16118399 | 0.84 | CCNC (0.40) | CCNCCDK8EPHX1ALDH1A1GFER | |
| SCHEMBL5500017 | 0.84 | TLR7 (0.36) | CSNK1DALDH1A1GFERMAPKAPK2LMNA | |
| SCHEMBL20540627 | 0.82 | NTRK1 (0.39) | ALDH1A1LMNACA1CA2CA12 | |
| SCHEMBL6427812 | 0.81 | NTRK1 (0.35) | LMNAPOLBCA1CA2CA12 | |
| SCHEMBL15856849 | 0.80 | NTRK1 (0.37) | LMNAPOLBCA1CA2CA12 | |
| SCHEMBL16078095 | 0.80 | L3MBTL1 (0.44) | EPHX1POLBNTRK1 | |
| Hydrochloric Acid SCHEMBL5497815 | 0.79 | NTRK1 (0.37) | LMNAPOLBCA1CA2CA12 | |
| SCHEMBL20540427 | 0.79 | CCNC (0.37) | CCNCCDK8EPHX1MAPKAPK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922435-B | Method for preparing ceftaroline from 7-aminocephalosporanic acid (7-ACA) | 桑多斯股份公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-9006421-B2 | Cephalosporin compositions and methods of manufacture | CUBIST PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| WO-2014152763-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CUBIST PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME LLC | 2014-09-18 | — | — | US | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | CCNC 731/4885CDK8 3858/4885CSNK1D 220/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | CCNC 1472/4885CDK8 4233/4885CSNK1D 143/4885 |
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | CCNC 1695/4885CDK8 795/4885CSNK1D 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.